HAC Biomed GmbH

HAC Biomed pioneered the evaluation of a new concept in in vivo tissue engineering, using autologous primary human hepatocytes isolated from diseased livers (explanted during orthotopic liver transplantation) to produce a neo-hybrid liver. The theory is to thus reduce immunogenicity, induce immunoregulation, and consequently minimize the need for extensive immunosuppression and eventually induce operational tolerance.

“Dr. Stange was responsible as an interim manager for building and running a certified clean room laboratory for the hepautocell individual therapy and has accompanied the commercialization and successful reimbursement strategy as a new examination and treatment method”

Milestones:

  • 2006: Company founded
  • 2008-2009: Served as interim COO
  • SilverSky engagement

Founded: 2006

contact

Silversky GmbH

Brunnenstrasse 23 40223 Düsseldorf
Germany

E-Mail: info@silversky-lifesciences.com

Impressum | Datenschutz

WRITE US AN EMAIL